Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by Northstar49on Oct 20, 2019 1:49pm

304 Views

Post# 30248870

Mid December

Last time Robert McWhirter was on BNN, he talked about it in great detail.

Time line to watch was Mid or Late December, when "he said" trial results would hit the news. It's all in that video.

It was also said that currently no other product like. Market is open for business, as it changed a molecule and has used sulphur to coat the pill, this has left each patient with a better experience.

If true, this will change the game very fast.

As Robert said, all will happen quickly for ATE. Watch the video to confirm, it is on BNN under that symbol.

Stay thirsty my friends....

Bullboard Posts

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal